DPP-4 inhibitors: 3/12 meta-analyses involving DPP-4 inhibitors show mortality risk decrease ranging from 12% to 42%, 1 shows mortality risk decrease of borderline significance, and 8/12 show non-significant association.
← all excerpts
Observational studies on the association of outpatient antidiabetic medication use and COVID-19 outcomes: are the findings more relevant to diabetes management than to COVID-19 pathology? A mini-review.
1
—
—